血清趋化因子网络与非小细胞肺癌化疗相关。

Serum chemokine network correlates with chemotherapy in non-small cell lung cancer.

作者信息

Yang Dawei, Zhou Jian, Zeng Tao, Yang Zhiyuan, Wang Xun, Hu Jie, Song Yuanlin, Chen Luonan, Peer Dan, Wang Xiangdong, Bai Chunxue

机构信息

Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Shanghai Respiratory Research Institute, Shanghai 200032, China.

Key Laboratory of Systems Biology, Innovation Center for Cell Signaling Network, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

出版信息

Cancer Lett. 2015 Aug 28;365(1):57-67. doi: 10.1016/j.canlet.2015.05.001. Epub 2015 May 11.

DOI:10.1016/j.canlet.2015.05.001

PMID:25976768

Abstract

OBJECTIVE

Inflammation plays an important role in the microenvironment of lung cancer. The present study aimed to evaluate the association of inflammatory biomarker networks with chemotherapies for patients with non-small cell lung cancer (NSCLC).

METHODS

The sera of healthy non-smokers (n = 14) and patients with NSCLC (n = 50), 36 with adenocarcinoma and 14 with squamous cell carcinoma, were collected. Healthy patients were untreated, while those with NSCLC were either chemotherapy-naïve or had received one and two courses of chemotherapy. The cytokine concentrations were measured using multiplexed cytokine immunoassays. The clinical informatics was scored with a Digital Evaluation Score System (DESS) to assess the severity of the patients. All patients completed follow-up for up to 2 years.

RESULTS

Among the 40 mediators measured, 13 significantly differed between patients with lung cancer and healthy controls, while 18 differed between untreated patients and those with stage IV adenocarcinoma who had undergone the first and second chemotherapy courses. The protein network of cytokines in NSCLC after multiple courses of chemotherapy was similar to that of normal persons. MIP-3α is the most crucial biomarker for predicting survival rates in NSCLC patients.

CONCLUSIONS

Our data identify an NSCLC-specific profile of inflammatory mediators that may be useful for cancer sub-classification, as well as the evaluation of therapeutic effects and overall survival.

摘要

目的

炎症在肺癌微环境中起重要作用。本研究旨在评估炎症生物标志物网络与非小细胞肺癌（NSCLC）患者化疗之间的关联。

方法

收集健康非吸烟者（n = 14）和NSCLC患者（n = 50）的血清，其中腺癌患者36例，鳞状细胞癌患者14例。健康患者未接受治疗，而NSCLC患者要么未接受过化疗，要么接受过一疗程或两疗程化疗。使用多重细胞因子免疫测定法测量细胞因子浓度。采用数字评估评分系统（DESS）对临床信息进行评分，以评估患者的严重程度。所有患者均完成了长达2年的随访。